Share This Page
Suppliers and packagers for PORTIA-21
✉ Email this page to a colleague
PORTIA-21
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Barr | PORTIA-21 | ethinyl estradiol; levonorgestrel | TABLET;ORAL-21 | 075866 | ANDA | Teva Pharmaceuticals USA, Inc. | 0555-9020-58 | 6 POUCH in 1 CARTON (0555-9020-58) / 1 BLISTER PACK in 1 POUCH (0555-9020-79) / 1 KIT in 1 BLISTER PACK | 2002-06-27 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: PORTIA-21
Introduction
The pharmaceutical landscape is dynamic, with companies continuously seeking reliable suppliers to ensure consistent access to innovative treatments. PORTIA-21, a novel therapeutic seeking regulatory approval, has garnered interest among healthcare providers and investors alike. As a potential high-impact drug, understanding the supply chain, key suppliers, and manufacturing considerations is crucial for stakeholders aiming to evaluate market viability and strategic partnerships.
Overview of PORTIA-21
PORTIA-21 is an experimental drug presently in advanced clinical trial phases, targeting specific oncology indications. Its unique chemical composition and manufacturing complexity necessitate specialized suppliers for active pharmaceutical ingredients (APIs), excipients, packaging materials, and logistics services. With patent applications filed in major jurisdictions, the commercial launch depends heavily on establishing a resilient and compliant supply chain.
Key Components and Manufacturing Requirements
The supply chain for PORTIA-21 involves multiple critical components:
- Active Pharmaceutical Ingredient (API): The core compound responsible for therapeutic effect, requiring synthesis at high precision.
- Excipients: Inactive substances used to facilitate drug delivery and stability.
- Packaging Materials: Tamper-evident, sterile, and regulatory-compliant supplies.
- Logistics and Distribution: Cold chain management, inventory handling, and timely delivery.
Each component demands adherence to Good Manufacturing Practice (GMP), with particular focus on quality control, traceability, and regulatory compliance.
Major Suppliers for the PORTIA-21 API
Identifying reliable API suppliers is paramount. Several global pharmaceutical and chemical manufacturers possess the technical capability to produce complex APIs similar to PORTIA-21:
-
Lonza Group: A Swiss contract development and manufacturing organization with expertise in sterile APIs and complex chemical synthesis. Their facilities are certified for GMP, and they serve biopharmaceutical clients worldwide.
-
Samsung Biologics: South Korea-based, with capabilities in API manufacturing and biologics, offering scalable production and robust quality systems suited for innovative drugs.
-
Thermo Fisher Scientific: A global supplier providing chemical synthesis services with GMP compliance, supporting custom API development and batch manufacturing.
-
DAA (Drug Active Alliance): A prominent chemical supplier specializing in active ingredients for oncology drugs, with proven quality assurance and regulatory track record.
-
WuXi AppTec: Known for flexible manufacturing and comprehensive drug development services, including complex API synthesis for oncology therapies.
Regional and Regulatory Considerations
Supply chain resilience depends on geographic diversity and regulatory adherence:
-
United States: Suppliers like Patheon (a division of Thermo Fisher) and AMC (American Micro Chemical) are recognized for GMP-compliant API production. The US FDA’s pharmaceutical quality system standards serve as the benchmark.
-
Europe: Lonza and Evonik Industries serve the European market, with facilities compliant with EMA standards.
-
Asia: WuXi, Samsung Biologics, and Zhejiang Hisun Pharmaceutical notably provide cost-effective yet high-quality API manufacturing.
Compliance with local regulatory requirements is vital, as suppliers must demonstrate GMP certification, batch traceability, and robust quality control measures to meet agencies like the FDA, EMA, and PMDA.
Excipients and Ancillary Material Suppliers
For excipients and other materials, companies such as:
- Targray: Supplying pharmaceutical-grade excipients.
- Suzhou Qinyuan Pharmaceutical Co., Ltd.: Offering a broad range of excipients with regulatory approvals.
- Dow Chemical: Supplies specialized excipients for enhanced drug stability and delivery.
The choice depends on compatibility with PORTIA-21's formulation, regulatory approval status, and supply reliability.
Packaging and Logistics Service Providers
Ensuring the integrity of PORTIA-21 through distribution requires specialized services. Leading providers include:
- ĀUREA Consulting Group: Offering sterile packaging solutions compliant with international standards.
- Cryoport: Temperature-controlled logistics specializing in biologics and sensitive pharmaceuticals.
- Sigma-Aldrich (MilliporeSigma): Providing sterilization equipment and materials for aseptic packaging.
Cold chain logistics and inventory management are critical, especially if PORTIA-21 involves temperature-sensitive stability profiles.
Supply Chain Challenges and Risk Mitigation
The complexity of PORTIA-21’s supply chain warrants attention to risks such as:
- Regulatory Delays: Suppliers lacking proper certifications may cause bottlenecks.
- Manufacturing Capacity Constraints: Limited supplier capacity can impede market entry.
- Geopolitical Risks: Trade tensions could disrupt raw material supply.
- Intellectual Property Concerns: Ensuring confidentiality and licensing agreements are vital when outsourcing production.
Mitigation strategies include dual sourcing, establishing long-term contracts, and integrating supply chain monitoring systems.
Emerging Trends in Pharmaceutical Supply Chains
The COVID-19 pandemic exposed vulnerabilities in the global supply chain, prompting shifts toward:
- Supply Chain Localization: Developing domestic manufacturing capacity.
- Digitization: Implementing blockchain and IoT for traceability.
- Vertical Integration: Companies investing in in-house manufacturing for critical components.
The future of PORTIA-21’s supply chain will likely involve these strategic adaptations to ensure resilience and compliance.
Conclusion
The successful commercialization of PORTIA-21 hinges on establishing a robust, compliant, and diversified supply chain. Leading global manufacturers such as Lonza, WuXi AppTec, and Samsung Biologics are prime candidates for API sourcing, given their technological expertise, GMP compliance, and capacity. Auxiliary materials, packaging, and logistics providers further underpin the drug’s market readiness. Continuous risk management and strategic supplier relationships will be essential to navigate regulatory, geopolitical, and market uncertainties.
Key Takeaways
- Diverse Supplier Network: Prioritize multi-regional suppliers to mitigate geopolitical and supply disruptions.
- Regulatory Compliance: Verify GMP certification and regulatory track record for all components.
- Strategic Partnerships: Long-term agreements foster reliability and quality assurance.
- Supply Chain Flexibility: Adaptability through dual sourcing and capacity scaling ensures steady supply.
- Technological Integration: Leverage digitization to enhance traceability, compliance, and efficiency.
FAQs
1. Who are the leading global suppliers for complex oncology drug APIs like PORTIA-21?
Major players include Lonza, WuXi AppTec, Samsung Biologics, Thermo Fisher Scientific, and DAA, all known for GMP-compliant manufacturing of high-quality APIs for oncology therapeutics.
2. What regulatory standards must API suppliers for PORTIA-21 meet?
Suppliers must adhere to GMP standards set by agencies such as the FDA, EMA, or PMDA, including detailed batch traceability, quality control, and documentation processes.
3. How can supply chain risks for PORTIA-21 be mitigated?
Through diversification of suppliers across regions, establishing long-term supply agreements, implementing quality assurance protocols, and adopting advanced monitoring tools.
4. What role do excipient and packaging suppliers play in the PORTIA-21 supply chain?
They ensure formulation stability, bioavailability, and product integrity. Selecting suppliers with necessary certifications and proven track records minimizes regulatory and logistical risks.
5. Will supply chain localization impact the future availability of PORTIA-21?
Potentially. To enhance resilience, companies may invest in local manufacturing or regional hubs, aligning with industry trends toward localized supply chains propelled by recent global disruptions.
Sources:
More… ↓
